Wasabi leaf has been reported to show human health benefits without assessment of its safety.This study aims to investigate the mutagenicity, acute and sub-acute toxicity and human trial safety of wasabi leafext. (WLE).The Ames test was used to assess mutagenicity, while acute and sub-acute toxicity were assessed by oral administration in five-week-old SIctlCR mice (SPF) and five-week-old Sprague-Dawley (SD) rats, resp.Human trial safety was further determined in a clin. trial.Twelve healthy subjects, aged 20-64 years and mildly obese (BM1 23.0 to 30.0 kg/m2), were enrolled in the clin. trial, and participants ingested 200 mg WLE daily for 12 wk.The effect of WLE on fat metabolism was evaluated by visceral fat area (VFA), s.c. fat area (SFA), VFA/SFA(V/S) area ratio, body weight, BMI, TC, T-Cho, HDL-C, LDL-C, waist circumference, and body fat percentage.In the Amcs test, WLE did not show mutagenicity in the range of 1.2-5000 pg/plate.No acute toxicity was observed in Slc:ICR mice (SPF) administered 5000 mg/kg/day WLE, and no sub-acute toxicity was observed in CrltCD (SD) rats administered 2500 mg/kg/day WLE.In the human clin. trial, there were no significant differences between the WLE and placebo groups for any outcome measure assessed.Thus, ingestion of200 mg/day of WLE was demonstrated for the first time to be safe.Taken together, our data on the mutagenicity, acute and sub-acute toxicity and human trial safety of WLE provide the first standard references for wasabi leaf supplement application.